Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. But some may not be satisfied with the prostate cancer med’s ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

Novartis NOVN-1.67%decrease; red down pointing triangle raised its guidance for the third time this year after higher third-quarter results topped expectations, boosted by revenue from its ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

The previous update I wrote on Novartis was the Q2 earnings preview and I want to note that while my estimates on some of the key growth products were off, the general direction of my prediction ...